Gevertz J[au] - Search Results

Year	Number of Results
2005	2
2006	1
2008	2
2009	2
2011	1
2012	1
2015	1
2016	4
2017	1
2018	1
2019	1
2020	1
2021	3
2022	2
2023	1

1

Guiding model-driven combination dose selection using multi-objective synergy optimization.

Gevertz JL, Kareva I. Gevertz JL, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1698-1713. doi: 10.1002/psp4.12997. Epub 2023 Jul 6. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37415306 Free PMC article.

2

From Fitting the Average to Fitting the Individual: A Cautionary Tale for Mathematical Modelers.

Luo MC, Nikolopoulou E, Gevertz JL. Luo MC, et al. Among authors: gevertz jl. Front Oncol. 2022 Apr 28;12:793908. doi: 10.3389/fonc.2022.793908. eCollection 2022. Front Oncol. 2022. PMID: 35574407 Free PMC article.

3

Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer.

Cárdenas SD, Reznik CJ, Ranaweera R, Song F, Chung CH, Fertig EJ, Gevertz JL. Cárdenas SD, et al. Among authors: gevertz jl. NPJ Syst Biol Appl. 2022 Sep 8;8(1):32. doi: 10.1038/s41540-022-00244-7. NPJ Syst Biol Appl. 2022. PMID: 36075912 Free PMC article.

4

Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.

Gevertz JL. Gevertz JL. Adv Exp Med Biol. 2016;936:191-208. doi: 10.1007/978-3-319-42023-3_10. Adv Exp Med Biol. 2016. PMID: 27739049

5

Mathematical model of real-time PCR kinetics.

Gevertz JL, Dunn SM, Roth CM. Gevertz JL, et al. Biotechnol Bioeng. 2005 Nov 5;92(3):346-55. doi: 10.1002/bit.20617. Biotechnol Bioeng. 2005. PMID: 16170827

6

Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment.

Greene JM, Gevertz JL, Sontag ED. Greene JM, et al. Among authors: gevertz jl. JCO Clin Cancer Inform. 2019 Apr;3:1-20. doi: 10.1200/CCI.18.00087. JCO Clin Cancer Inform. 2019. PMID: 30969799 Free PMC article.

7

Predicting the impact of placing an overdose prevention site in Philadelphia: a mathematical modeling approach.

Wares JR, Dong J, Gevertz JL, Radunskaya A, Viner K, Wiebe D, Solomon S. Wares JR, et al. Among authors: gevertz jl. Harm Reduct J. 2021 Oct 30;18(1):110. doi: 10.1186/s12954-021-00559-4. Harm Reduct J. 2021. PMID: 34717657 Free PMC article.

8

Growing heterogeneous tumors in silico.

Gevertz J, Torquato S. Gevertz J, et al. Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Nov;80(5 Pt 1):051910. doi: 10.1103/PhysRevE.80.051910. Epub 2009 Nov 16. Phys Rev E Stat Nonlin Soft Matter Phys. 2009. PMID: 20365009

9

Developing a Minimally Structured Mathematical Model of Cancer Treatment with Oncolytic Viruses and Dendritic Cell Injections.

Gevertz JL, Wares JR. Gevertz JL, et al. Comput Math Methods Med. 2018 Oct 30;2018:8760371. doi: 10.1155/2018/8760371. eCollection 2018. Comput Math Methods Med. 2018. PMID: 30510594 Free PMC article.

10

Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance.

Pérez-Velázquez J, Gevertz JL, Karolak A, Rejniak KA. Pérez-Velázquez J, et al. Among authors: gevertz jl. Adv Exp Med Biol. 2016;936:149-164. doi: 10.1007/978-3-319-42023-3_8. Adv Exp Med Biol. 2016. PMID: 27739047 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

23 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year